» Articles » PMID: 21644031

Human NK Cells in Acute Myeloid Leukaemia Patients: Analysis of NK Cell-activating Receptors and Their Ligands

Abstract

Natural killer (NK) cell activation is strictly regulated to ensure that healthy cells are preserved, but tumour-transformed or virus-infected cells are recognized and eliminated. To carry out this selective killing, NK cells have an ample repertoire of receptors on their surface. Signalling by inhibitory and activating receptors by interaction with their ligands will determine whether the NK cell becomes activated and kills the target cell. Here, we show reduced expression of NKp46, NKp30, DNAM-1, CD244 and CD94/NKG2C activating receptors on NK cells from acute myeloid leukaemia patients. This reduction may be induced by chronic exposure to their ligands on leukaemic blasts. The analysis of ligands for NK cell-activating receptors showed that leukaemic blasts from the majority of patients express ligands for NK cell-activating receptors. DNAM-1 ligands are frequently expressed on blasts, whereas the expression of the NKG2D ligand MICA/B is found in half of the patients and CD48, a ligand for CD244, in only one-fourth of the patients. The decreased expression of NK cell-activating receptors and/or the heterogeneous expression of ligands for major receptors on leukaemic blasts can lead to an inadequate tumour immunosurveillance by NK cells. A better knowledge of the activating receptor repertoire on NK cells and their putative ligands on blasts together with the possibility to modulate their expression will open new possibilities for the use of NK cells in immunotherapy against leukaemia.

Citing Articles

Immune-dysregulation harnessing in myeloid neoplasms.

Sharifi M, Xu L, Nasiri N, Ashja-Arvan M, Soleimanzadeh H, Ganjalikhani-Hakemi M Cancer Med. 2024; 13(17):e70152.

PMID: 39254117 PMC: 11386321. DOI: 10.1002/cam4.70152.


Unveiling mitochondrial and ribosomal gene deregulation and tumor microenvironment dynamics in acute myeloid leukemia.

Ma C, Hao Y, Shi B, Wu Z, Jin D, Yu X Cancer Gene Ther. 2024; 31(7):1034-1048.

PMID: 38806621 DOI: 10.1038/s41417-024-00788-2.


Differential co-expression network analysis elucidated genes associated with sensitivity to farnesyltransferase inhibitor and prognosis of acute myeloid leukemia.

Kelesoglu N, Kori M, Karademir Yilmaz B, Duru O, Arga K Cancer Med. 2023; 12(24):22420-22436.

PMID: 38069522 PMC: 10757125. DOI: 10.1002/cam4.6804.


CAR-NK cells for acute myeloid leukemia immunotherapy: past, present and future.

Zhang L, Meng Y, Yao H, Zhan R, Chen S, Miao W Am J Cancer Res. 2023; 13(11):5559-5576.

PMID: 38058830 PMC: 10695781.


The Power of Three: Nanomaterials for Natural Killer (NK) Cell Immunoengineering Maximize Their Potency if They Exploit Multireceptor Stimulation.

Dodd H, Guerra N, Dunlop I Adv Healthc Mater. 2023; 13(5):e2302297.

PMID: 38029341 PMC: 11468765. DOI: 10.1002/adhm.202302297.


References
1.
Sivori S, Parolini S, Falco M, Marcenaro E, Biassoni R, Bottino C . 2B4 functions as a co-receptor in human NK cell activation. Eur J Immunol. 2000; 30(3):787-93. DOI: 10.1002/1521-4141(200003)30:3<787::AID-IMMU787>3.0.CO;2-I. View

2.
Bjorkstrom N, Ljunggren H, Sandberg J . CD56 negative NK cells: origin, function, and role in chronic viral disease. Trends Immunol. 2010; 31(11):401-6. DOI: 10.1016/j.it.2010.08.003. View

3.
Sanchez C, Le Treut T, Boehrer A, Knoblauch B, Imbert J, Olive D . Natural killer cells and malignant haemopathies: a model for the interaction of cancer with innate immunity. Cancer Immunol Immunother. 2010; 60(1):1-13. PMC: 11029698. DOI: 10.1007/s00262-010-0898-x. View

4.
Chan A, Hong D, Atzberger A, Kollnberger S, Filer A, Buckley C . CD56bright human NK cells differentiate into CD56dim cells: role of contact with peripheral fibroblasts. J Immunol. 2007; 179(1):89-94. DOI: 10.4049/jimmunol.179.1.89. View

5.
Lakshmikanth T, Burke S, Ali T, Kimpfler S, Ursini F, Ruggeri L . NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo. J Clin Invest. 2009; 119(5):1251-63. PMC: 2673866. DOI: 10.1172/JCI36022. View